Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Cara Therapeutics, Inc.    CARA

CARA THERAPEUTICS, INC.

(CARA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Cara Therapeutics to Present at Multiple Upcoming Investor Conferences

11/11/2020 | 07:00am EST

STAMFORD, Conn., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, today announced that Derek Chalmers, Ph.D., D.Sc., President and Chief Executive Officer, will participate in the following upcoming virtual investor conferences and events in November and December:

Stifel 2020 Virtual Healthcare Conference, November 16, 2020 – November 18, 2020
Fireside Chat on Monday, November 16, 2020 at 8:40 a.m. ET

Jefferies Virtual London Healthcare Conference, November 17, 2020 – November 19, 2020
Fireside Chat on Thursday, November 19, 2020 at 9:40 a.m. ET

Piper Sandler Virtual Healthcare Conference, December 1, 2020 – December 3, 2020
Pre-recorded Fireside Chat Available on Monday, November 23, 2020 at 10:00 a.m. ET

Webcasts of the fireside chats can be accessed under "Events & Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. Archived webcast recordings will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. In two Phase 3 trials, KORSUVA Injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). Cara has successfully completed its Phase 2 trial of Oral KORSUVA for the treatment of pruritus in patients with CKD and is currently conducting Phase 2 trials of Oral KORSUVA in atopic dermatitis and primary biliary cholangitis patients with moderate-to-severe pruritus.

The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

INVESTOR CONTACT:
Janhavi Mohite
Stern Investor Relations, Inc.
212-362-1200
janhavi.mohite@SternIR.com

MEDIA CONTACT:
Annie Starr
6 Degrees
973-415-8838
astarr@6degreespr.com

Primary Logo


© GlobeNewswire 2020
All news about CARA THERAPEUTICS, INC.
01/12CARA THERAPEUTICS : Initiates Phase 2 Trial of Oral KORSUVA for the Treatment of..
AQ
01/11CARA THERAPEUTICS : Begins Phase II Study of Difelikefalin for Treatment of Prur..
MT
01/11Cara Initiates Phase 2 Trial of Oral KORSUVA™ for the Treatment of Prur..
GL
01/06CARA THERAPEUTICS : to Present at the 39th Annual J.P. Morgan Healthcare Confere..
AQ
2020CARA THERAPEUTICS : Submits New Drug Application to U.S. Food and Drug Administr..
AQ
2020CARA THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exh..
AQ
2020CARA THERAPEUTICS : Submits New Drug Application for Korsuva Injection
MT
2020Cara Therapeutics Submits New Drug Application to U.S. Food and Drug Administ..
GL
2020SWK : ' Subsidiary, Enteris BioPharma, Receives $2.5Million Milestone Payment fr..
MT
2020CARA THERAPEUTICS : SWK Holdings' Subsidiary, Enteris BioPharma, Receives Second..
PR
More news
Financials (USD)
Sales 2020 65,7 M - -
Net income 2020 -53,3 M - -
Net Debt 2020 - - -
P/E ratio 2020 -13,2x
Yield 2020 -
Capitalization 924 M 924 M -
Capi. / Sales 2020 14,1x
Capi. / Sales 2021 32,8x
Nbr of Employees 76
Free-Float 83,9%
Chart CARA THERAPEUTICS, INC.
Duration : Period :
Cara Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CARA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Average target price 33,50 $
Last Close Price 19,18 $
Spread / Highest target 109%
Spread / Average Target 74,7%
Spread / Lowest Target 9,49%
EPS Revisions
Managers and Directors
NameTitle
Derek T. Chalmers President, Chief Executive Officer & Director
Thomas Reilly Chief Financial & Accounting Officer
Frèdèrique Menzaghi Chief Scientific Officer, Senior VP-R&D
Joana Goncalves Chief Medical Officer
Martin A. Vogelbaum Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CARA THERAPEUTICS, INC.22.60%956
MODERNA, INC.45.35%60 120
LONZA GROUP AG5.49%50 227
CELLTRION, INC.-10.58%39 891
IQVIA HOLDINGS INC.0.65%34 576
SEAGEN INC.-1.43%31 230